Peptides could fast-track Hims & Hers' patient network like Harry Potter did for Amazon. Its US-based supply chain, manufacturing and clinical network could serve new demand. The FDA's interim compounding policy cleared White House review and may be released any day, potentially allowing certain peptides; Lee Rosebush says six are in Category 1. The policy's terms remain unknown. x.com  x.com  x.com  x.com 

RFK Jr.'s health department's notice that the FDA will not take action against pharmacies compounding six unapproved peptides brings Hims & Hers' peptide opportunity forward. Pharmacies can offer BPC-157, TB-500, epitalon, KPV, MOTS-c and semax now while a formal rule change is worked on. This is the most bullish news for Hims & Hers. x.com 

Hims & Hers faces mounting headwinds from an FTC lawsuit and a setback to its peptide expansion. The FTC alleges deceptive subscription practices and improper sharing of sensitive health data with ad platforms. An FDA advisory panel also voted against adding emideltide to the 503A Bulks List, a blow to Hims' peptide and compounding plans. x.com 

Hims & Hers could gain a massive new growth opportunity if peptide access expands after the White House completed its review of the FDA's interim policy. Six peptides, including BPC-157, TB-500 and MOTS-c, could gain expanded access; Hims is preparing treatments. The potential market is $2B-$3B. x.com 

Hims & Hers' newly previewed Peptides+ offering could add a growth vertical to its healthcare platform. Management plans access to sermorelin, glutathione and NAD+; recent regulatory developments may also open a path for BPC-157 and TB-500, subject to further conditions. Rollout and commercial opportunity remain unproven, and margins and execution are still risks. x.com 

Hims & Hers looks bearish on news that Chinese producers are moving into bootleg peptides sold in the US. Per a WSJ report shared by @tradfi, Chinese fentanyl precursor producers are pivoting to selling bootleg peptides in the US, and several Chinese peptide vendors were previously indicted in the US over the fentanyl trade. x.com 

A draft HHS policy opening a regulated path for peptides advances Hims & Hers' peptide opportunity. CEO Andrew Dudum says its planned Peptides+ rollout would use clinician-led protocols and a fully US-based manufacturing and supply chain; the policy is still a draft. x.com 

Hims & Hers' peptide capabilities may be underappreciated, setting up a strong bounce after peptide news. Per @riyadosofian, it is the only telehealth company with a peptide facility and global distribution system. A strong bounce is expected now as the stock holds outside its wedge. x.com  x.com 

Hims & Hers will keep missing if Eli Lilly protects retatrutide with a biologic patent and traditional GLP-1 prices keep falling. Other peptides beyond GLP-1s are years away, and there are not enough effective and safe ones to drive meaningful revenue. x.com  x.com  x.com 

With 29% of its shares sold short, Hims & Hers is set up to rally after an FDA panel voted 8–6, with one abstention, in favor of BPC-157, per @OracleNYSE. It looks like a decent swing over the next few days, as @TraderZ suggests. x.com  x.com